by Mark L. Ratner
The audience at just about any presentation from high-tech communications manufacturer Motorola Inc. , whether oriented toward engineering, science, or business, is likely to be reminded early on that...
Motorola is developing an expertise in microarray manufacturing to use as the jump-off point for a new life sciences initiative it hopes will turn into a high-margin, high-growth diagnostics business. It has spent $500 million in external investments to support the venture, including the $280 million acquisition of a clinical diagnostics start-up. But with its investors concerned with the recent downturn in demand in its core high-tech manufacturing businesses, the company is understandably reticent about touting the possibility of life sciences being its next big thing. On the other hand, should Motorola gain momentum and demonstrate an ability to tap the clinical diagnostics markets, the biochip initiative could ultimately become a broad-based point-of-care play, with the company drawing on its expertise in wireless communications to produce interactive handheld devices that would capture and transmit data to a remote site for analysis.
by Mark L. Ratner
The audience at just about any presentation from high-tech communications manufacturer Motorola Inc. , whether oriented toward engineering, science, or business, is likely to be reminded early on that...
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.